Compositions and methods for lowering triglycerides in a subject having reduced kidney function

1. A method of preventing progression of stage 3 chronic kidney disease in a subject having an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m 2 for at least 3 months, the method comprising administering to the subject about 4 g ethyl eicosapentaenoate (E-EPA) per day for a period of at least 12 weeks.

2. The method of claim 1 , wherein the subject further has diabetes mellitus and/or a high sensitivity C-reactive protein (hsCRP) level of at least about 2.0 mg/L.

3. The method of claim 2 , wherein the subject has a fasting baseline triglyceride level of about 200 mg/dL to about 500 mg/dL and/or low density lipoprotein cholesterol (LDL-C) levels between about 40 mg/dL and about 115 mg/dL.

4. The method of claim 3 , wherein the subject has an estimated glomerular filtration rate (eGFR) of about 50 mL/min/1.73 m 2 for at least about 3 months.

5. The method of claim 4 , wherein the subject exhibits a reduction in one or more parameters selected from the group consisting of non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), very low-density lipoprotein cholesterol (vLDL-C), lipoprotein associated phospholipase A2 (Lp-PLA2), apolipoprotein B (Apo B), apolipoprotein-C III (Apo C-III), high density lipoprotein cholesterol (HDL-C), remnant lipoprotein cholesterol (RLP-C), and very low density lipoprotein triglyceride (vLDL-TG).

6. The method of claim 1 , wherein the subject has a fasting baseline triglyceride level of about 200 mg/dL to about 500 mg/dL and LDL-C control.

7. The method of claim 6 , wherein after administration of the composition, the subject experiences a reduction in triglycerides and cardiovascular risk factors without raising LDL-C compared to a placebo control.